Publications 2001

Bannasch P., Nehrbass D., Kopp-Schneider A.: Significance of hepatic preneoplasia for cancer chemoprevention. IARC Sci.Publ. 154 (2001) 223-240.

Bartoszynski R., Edler L., Hanin L., Kopp-Schneider A., Pavlova L., Tsodikov A., Zorin A., Yakovlev A.Y.: Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math.Biosci. 171 (2001) 113-142.

Benner A., Edler L., Hartung G.: Design and analysis of phase I trials in clinical oncology. In: S.P.Millard, A.Krause (Eds.), Applied statistics in the pharmaceutical industry. With case studies using S-Plus. Springer, New York, 2001, pp.189-216.

Breitkreutz R., Wagner J., Tokus M., Benner A., Rossol S., Pittack N., Stein J., Dröge W., Holm E.: Flux of amino acids and energy substrates across the leg in weight-stable HIV infected patients with acute opportunistic infections: indication of a slow protein wasting process. J.Mol.Med. 79 (2001) 671-678.

Chariyalertsak S., Sirikulchayanonta V., Mayer D., Kopp-Schneider A., Fürstenberger G., Marks F., Müller-Decker K.: Aberrant cyclooxygenase isoenzyme expression in human intrahepatic cholangiocarcinoma. Gut 48 (2001) 80-86.

Dally H., Bartsch H., Drings P., Schulz V., Kayser K., Dienemann H., Spiegelhalder B., Jäger B., Gassner K., Edler L., Schmezer P., Risch A.: Distribution of myeloperoxidase (MPO) G-463 A variant alleles in lung cancer histological subtypes. J.Cancer Res.Clin.Oncol. 127(Suppl.), 83 (CR22). 2001.

Deichmann M., Benner A., Kuner N., Wacker J., Waldmann V., Naeher H.: Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100b or melanoma inhibitory activity (MIA)? Melanoma Res. 11 (2001) 291-296.

Dencausse Y., Sturm J., Hartung G., Diezler P., Edler L., Bambach M., Wojatschek C., Lindemann H., Queisser W.: Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility. Onkol. 24 (2001) 476-480.

Dencausse Y., Sturm J., Diezler P., Edler L., Hartung G., Bambach M., Wojatschek C., Lindemann H., Queisser W.: Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hours-infusion of high dose 5-fluorouracil and folinic acid: evaluation of feasibility. Onkol. 24(3), 308. 2001.

Edler L.: IASC Outgoing president's report. Comput.Statist.Data Anal. 38 (2001) 115-120.

Edler L., Muttray A., Jung D., Rose D.M., Konietzko J., Portier C.J., Heinzl H.: Exploring possible dose-response relationships between exposure to PCDDs/Fs and acquired dyschromatopsia in humans. Organohalogen Comp. 53 (2001) 309-312.

Edler L.: Quantitative methods for food and diet safety assessment. 1, 309-312. 2001. Bull.Int.Statist.Inst. ISI 53nd Session Book 1.

Edler L.: Cellular response II. Statistical methods for toxicity detection and testing. Folia histochem.cytobiol. 39(Suppl.1), 13-14. 2001.

Edler L.: Overview of phase I trials. In: J.Crowley (Ed.), Handbook of Statistics in Clinical Oncology. Dekker, New York, 2001, pp.1-34.

Edler L., Grassmann J., Suhai S.: Role and results of statistical methods in protein fold class prediction. Math.Comput.Model. 33 (2001) 1401-1417.

Edler L.: Statistische Bewertung von Therapieergebnissen. In: J.R.Siewert (Ed.), Onkologische Chirurgie. Springer, Heidelberg, 2001, pp.305-319.

Erles K., Rohde V., Thaele M., Roth S., Edler L., Schlehofer J.R.: DNA of adeno-associated virus (AAV) in testicular tissue and in abnormal semen samples. Hum.Reproduct. 16 (2001) 2333-2337.

Gassner K., Dally H., Jäger B., Schmezer P., Spiegelhalder B., Edler L., Drings P., Dienemann H., Kayser K., Schulz V., Bartsch H., Risch A.: Gender differences in the role of genetic polymorphisms of CYP1B1 in susceptibility to lung cancer. J.Cancer Res.Clin.Oncol. 127(Suppl.), 83 (CR21). 2001.

Geisler I.: Stochastische Modelle für den Mechanismus der Entstehung und der Progression von Krebsvorstufen in der Leber. (Dissertation). 2001. Fachbereich Statistik, Univ.Dortmund.

Heinzl H., Edler L.: Assessing uncertainty in toxicokinetic models of human life long exposure to TCDD. Conference of the International Society for Environmental Epidemiology , Abstract-No. ISEE560. 2001.

Heinzl H., Edler L.: Toxicokinetics of human life long exposure to carcinogenic agents: an application to TCDD. J.Cancer Res.Clin.Oncol. 127(Suppl.), 84 (CR24). 2001.

Int.Molecular Genetic Study of Autism Consortium (IMGSAC), (Benner A.: Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum.Mol.Genet. 10 (2001) 973-982.

Kienle P., Weitz J., Reinshagen S., Magener A., Autschbach F., Benner A., Stern J., Herfarth C.: Association of decreased perfusion of the ileoanal pouch mucosa with early postoperative pouchitis and local septic complications. Arch.Surg. 136 (2001) 1124-1130.

Koch M., Weitz J., Kienle P., Benner A., Willeke F., Lehnert T., Herfarth C., Knebel-Doeberitz M.v.: Comparative analysis of tumor cell dissemination in mesenteric, central, and peripheral venous blood in patients with colorectal cancer. Arch.Surg. 136 (2001) 85-89.

Kopp-Schneider A., Lutz W.K.: J-Shaped dose-response relationship for tumor induction by caffeic acid in the rat forestomach, modeled by non-monotonic dose response for DNA damage and cell proliferation. Hum.Ecol.Risk Assess. 7 (2001) 921-931.

Kopp-Schneider A., Edler L.: Complex mechanistic carcinogenicity modeling. Folia histochem.cytobiol. 39(Suppl.1), 14. 2001.

Kopp-Schneider A.: Using a stochastic model to analyze the sequence of phenotypic changes in rat liver focal lesions. Math.Comput.Model. 33 (2001) 1289-1295.

Kösters R., Hans M.A., Benner A., Prosst R., Boehm J., Gahlen J., Doeberitz M.K.: Predominant mutation of codon 41 of the beta-catenin proto-onocogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol. Carcinogen. 22 (2001) 1885-1890.

Kröber A., Seiler T., Benner A., Lichter P., Döhner H., Stilgenbauer S.: VH mutation status, CD38 expression, chromosomal aberrations and survival in CLL. Onkol. 24(S6), 90. 2001.

Kübler A.C., Reuther T., Staff C., Haase T., Flechtenmacher C., Benner A., Scheer M., Zillmann U.: Klinische Wirksamkeit von m-THPC-PEG in einem neuen xenogenen Tumortiermodell für humane Plattenepithelkarzinome. Mund-Kiefer-GesichtsChir. 5 (2001) 105-113.

Laack E., Mende T., Benk J., Chemaissani A., Scholtze J., Lorenz C., Niestroy A., Dalhoff K., Müller T., Walter T., Dürk H., Edler L., Hossfeld D.K.: Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Europ.J.Cancer 37 (2001) 583-590.

Lacroix J., Becker H.D., Wörner S.M., Rittgen W., Drings P., Knebel-Doeberitz M.v.: Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int.J.Cancer 92 (2001) 1-8.

Manegold C., Pilz L., Koschel G., Schott K., Hruska D., Mezger J.: Single agent gemzar (G) and taxotere (T) given as 1st/2nd line therapy are active in advanced NSCLC: survival data from two randomized phase II studies. Europ.J.Cancer 37(Suppl.6), 20. 2001.

Manegold C., Pilz L., Koschel G., Schott K., Hruska D., Mezger J.: Single agent Gemcitabine (G) and Docetaxel (D) given sequentially in various doses and schedules are effective in advanced NSCLC: Survival data from two (I, II) randomized phase II studies. Proc.ASCO 337a, 1346. 2001.

Möhler T.M., Neben K., Benner A., Egerer G., Krasniqi F., Ho A.D., Goldschmidt H.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98 (2001) 3846-3848.

Möhler T.M., Goldschmidt H., Neben K., Kasper B., Hawighorst H., van Kaick G., Benner A., Reusch P., Ho A.D., Marme D., Drevs J.: Plasma concentrations of soluble endothelial specific tyrosine kinase receptors (Stie2/Sflt-1) correlate with disease activity markers and functional magnetic resonance imaging parameters in multiple myeloma. Onkol. 24(S6), 147. 2001.

Möhler T.M., Hawighorst H., Neben K., Egerer G., Hillengass J., Max R., Benner A., Ho A.D., van Kaick G., Goldschmidt H.: Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int.J.Cancer 93 (2001) 862-868.

Neben K., Möhler T.M., Egerer G., Krämer A., Hillengass J., Benner A., Ho A.D., Goldschmidt H.: High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin.Cancer Res. 7 (2001) 2675-2681.

Neben K., Möhler T.M., Krämer A., Benner A., Egerer G., Ho A.D., Goldschmidt H.: Response to thalidomide in progressive multiple myeloma is not medicated by inhibition of angiogenic cytokine secretion. Brit.J.Haematol. 115 (2001) 605-608.

Rajaee-Behbahani N., Schmezer P., Risch A., Rittgen W., Kayser K., Dienemann H., Schulz V., Drings P., Thiel S., Bartsch H.: Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int.J.Cancer 95 (2001) 86-91.

Risch A., Wikman H., Thiel S., Schmezer P., Edler L., Drings P., Dienemann H., Kayser K., Schulz V., Spiegelhalder B., Bartsch H.: Glutathione-S-transferase M1, M3, T1and P1 polymorphisms and susceptibility to non-small cell lung cancer subtypes and hamartomas. Pharmacogen. 11 (2001) 757-764.

Rittgen W., Becker N.: Statistical issues of quality control in organised breast cancer screening. J.Epidem.Biostat. 6 (2001) 425-432.

Schmezer P., Rajaee-Behbahani N., Risch A., Thiel S., Rittgen W., Drings P., Dienemann H., Kayser K., Schulz V., Bartsch H.: Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagen. 16 (2001) 25-30.

Stassar M.J.J.G., Devitt G., Brosius M., Rinnab L., Prang J., Schradin T., Simon J., Petersen S., Kopp-Schneider A., Zöller M.: Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Brit.J.Cancer 85 (2001) 1372-1382.

Stilgenbauer S., Bullinger L., Kröber A., Benner A., Lichter P., Döhner H.: Molecular genetics of CLL: genomic aberration and IgV mutation status in pathogenesis and clinical course. Onkol. 24(S6), 25. 2001.

Su Q., Wang S.F., Chang T.E., Breitkreutz R., Hennig H., Takegoshi K., Edler L., Schröder C.H.: Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin.Cancer Res. 7 (2001) 2005-2015.

Walz C.M., Nakamura M., Fukunaga T., Jasiewicz Y., Edler L., Schlehofer J.R., Tanaka Y.: Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma. J.Med.Virol. 65 (2001) 185-189.

Wikman H., Thiel S., Jäger B., Schmezer P., Spiegelhalder B., Edler L., Dienemann H., Kayser K., Schulz V., Drings P., Bartsch H., Risch A.: Relevance of n-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogen. 11 (2001) 157-168.

Wüllenweber H.P., Sutter C., Autschbach F., Willeke F., Kienle P., Benner A., Bähring J., Kadmon M., Herfarth C., Knebel-Doeberitz M.v., Gebert J.: Evaluation of Bethesda guidelines in relation to microsatellite instability. Dis Col.Rectum 44 (2001) 1281-1289.

Zehbe I., Voglino G., Wilander E., Delius H., Marongiu A., Edler L., Klimek F., Andersson S., Tommasino M.: p53 Codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 61 (2001) 608-611.